Regeneron Pharmaceuticals (REGN)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Jan 8, 2013)8-K (Oct 24, 2012)8-K (Jul 25, 2012)8-K (Jun 14, 2012)8-K (May 8, 2012)8-K (Apr 26, 2012)8-K (Feb 13, 2012)8-K (Jan 24, 2012)8-K (Jan 10, 2012)8-K (Jan 3, 2012)8-K (Dec 21, 2011)8-K (Dec 5, 2011)8-K (Nov 22, 2011)8-K (Nov 21, 2011)8-K (Nov 14, 2011)8-K (Nov 3, 2011)8-K (Oct 27, 2011)8-K (Oct 24, 2011)8-K (Oct 19, 2011)8-K (Oct 18, 2011)8-K (Sep 26, 2011)8-K (Sep 15, 2011)8-K (Aug 22, 2011)8-K (Aug 17, 2011)8-K (Jul 28, 2011)8-K (Jun 27, 2011)8-K (Jun 21, 2011)8-K (Jun 15, 2011)8-K (May 3, 2011)8-K (Apr 27, 2011)8-K (Apr 26, 2011)8-K (Apr 18, 2011)8-K (Mar 10, 2011)8-K (Feb 28, 2011)8-K (Feb 18, 2011)8-K (Dec 27, 2010)8-K (Dec 20, 2010)8-K (Nov 22, 2010)8-K (Nov 15, 2010)8-K (Oct 28, 2010)8-K (Oct 13, 2010)8-K (Jul 29, 2010)8-K (Jun 14, 2010)8-K (Jun 10, 2010)8-K (May 13, 2010)8-K (Apr 29, 2010)8-K (Feb 19, 2010)8-K (Feb 16, 2010)8-K (Dec 8, 2009)8-K (Nov 12, 2009)8-K (Nov 4, 2009)8-K (Sep 14, 2009)8-K (Aug 4, 2009)8-K (Jun 11, 2009)8-K (May 1, 2009)8-K (Feb 26, 2009)8-K (Jan 9, 2009)8-K (Nov 20, 2008)8-K (Nov 4, 2008)8-K (Sep 4, 2008)8-K (Jul 31, 2008)8-K (Jul 3, 2008)8-K (Jun 17, 2008)8-K (Jun 4, 2008)8-K (May 21, 2008)8-K (May 2, 2008)8-K (Apr 8, 2008)8-K (Feb 29, 2008)8-K (Feb 28, 2008)8-K (Dec 21, 2007)8-K (Nov 29, 2007)8-K (Nov 13, 2007)8-K (Nov 6, 2007)8-K (Nov 2, 2007)8-K (Oct 29, 2007)8-K (Oct 1, 2007)8-K (Aug 14, 2007)8-K (Aug 1, 2007)8-K (Jun 8, 2007)8-K (May 3, 2007)8-K (Apr 3, 2007)8-K (Mar 2, 2007)8-K (Feb 6, 2007)8-K (Dec 22, 2006)8-K (Nov 20, 2006)8-K (Nov 16, 2006)8-K (Nov 7, 2006)8-K (Oct 31, 2006)8-K (Oct 18, 2006)8-K (Sep 8, 2006)8-K (Aug 3, 2006)8-K (Jun 9, 2006)8-K (Jun 1, 2006)8-K (May 5, 2006)8-K (May 2, 2006)8-K (Apr 19, 2006)8-K (Feb 24, 2006)8-K (Feb 3, 2006)8-K (Jan 31, 2006)8-K (Jan 25, 2006)8-K (Dec 23, 2005)8-K (Dec 22, 2005)8-K (Dec 16, 2005)8-K (Nov 3, 2005)8-K (Sep 26, 2005)8-K (Aug 4, 2005)8-K (Jul 1, 2005)8-K (May 17, 2005)8-K (Apr 28, 2005)8-K (Apr 14, 2005)8-K (Feb 23, 2005)8-K (Feb 4, 2005)8-K (Jan 11, 2005)8-K (Jan 6, 2005)8-K (Dec 17, 2004)8-K (Dec 13, 2004)8-K (Nov 17, 2004)8-K (Nov 12, 2004)8-K (Oct 28, 2004)8-K (Jul 27, 2004)8-K (Apr 28, 2004)8-K (Apr 27, 2004)8-K (Mar 1, 2004)8-K (Feb 24, 2004)8-K (Oct 31, 2003)8-K (Oct 8, 2003)8-K (Sep 9, 2003)8-K (Aug 1, 2003)8-K (May 5, 2003)8-K (Apr 16, 2003)8-K (Apr 1, 2003)8-K (Feb 6, 2003)8-K (Jan 21, 2003)8-K (Jul 25, 2002)8-K (Jul 11, 2002)8-K (Jul 8, 2002)8-K (Oct 12, 2001)8-K (Jan 26, 2001)8-K (Jan 25, 2001)8-K (Apr 4, 2000)8-K (Mar 29, 2000)8-K (May 14, 1997)8-K (Jan 16, 1997)

Other

Regeneron Pharmaceuticals 8-K 2012

Documents found in this filing:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2012 (January 20, 2012)

REGENERON PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

New York	000-19034	13-3444607
(State or other jurisdiction of	(Commission File No.)	(IRS Employer Identification No.)
Incorporation)

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707

(Address of principal executive offices, including zip code)

(914) 347-7000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

EXPLANATORY NOTE

This Current Report on Form 8-K/A is being filed to amend the Current Report on Form 8-K filed by Regeneron Pharmaceuticals, Inc. (“Regeneron”) on November 22, 2011 (the “Original Report”). On November 18, 2011, the Board of Directors of Regeneron (the “Board”) elected Marc Tessier-Lavigne, Ph.D. as a director of Regeneron. This election was reported in the Original Report. At the time of the filing of the Original Report, board committee appointments for Dr. Tessier-Lavigne had not yet been determined. The sole purpose of this report is to disclose this information that was not determined at that time.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 20, 2012, the Board appointed Marc Tessier-Lavigne, Ph.D to the Compensation Committee and the Technology Committee.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 24, 2012	REGENERON PHARMACEUTICALS, INC.


	By:	/s/ Joseph J. LaRosa
	Name: Joseph J. LaRosa
	Title: Senior Vice President, General Counsel and
	Secretary

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

Regeneron Pharmaceuticals (REGN)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: